Eiropas Savienība - zviedru - EMA (European Medicines Agency)

novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - andra antineoplastiska medel - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.

Zviedrija - zviedru - Läkemedelsverket (Medical Products Agency)

instituto grifols sa - immunglobulin, humant normalt - injektionsvätska, lösning - 200 mg/ml - immunglobulin, humant normalt 200 mg aktiv substans

Eiropas Savienība - zviedru - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antineoplastiska medel - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Zviedrija - zviedru - Läkemedelsverket (Medical Products Agency)

desitin arzneimittel gmbh - karbamazepin - depottablett - 150 mg - karbamazepin 150 mg aktiv substans - karbamazepin

Zviedrija - zviedru - Läkemedelsverket (Medical Products Agency)

desitin arzneimittel gmbh - karbamazepin - depottablett - 200 mg - karbamazepin 200 mg aktiv substans - karbamazepin

Zviedrija - zviedru - Läkemedelsverket (Medical Products Agency)

desitin arzneimittel gmbh - karbamazepin - depottablett - 400 mg - karbamazepin 400 mg aktiv substans - karbamazepin

Eiropas Savienība - zviedru - EMA (European Medicines Agency)

janssen-cilag international n.v. - daratumumab - multipelt myelom - monoclonal antibodies and antibody drug conjugates, antineoplastic agents - multiple myelomadarzalex is indicated: in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. i kombination med bortezomib, talidomid och dexametason för behandling av vuxna patienter med nyligen fått diagnosen multipelt myelom som är berättigade till autolog stamcellstransplantation. i kombination med lenalidomid och dexametason, eller bortezomib och dexametason, för behandling av vuxna patienter med multipelt myelom som har fått minst en tidigare behandling. in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy (see section 5. som monoterapi för behandling av vuxna patienter med återfall och eldfasta multipelt myelom, vars tidigare behandling ingår en proteasom-hämmare och en immunmodulerande substans avsedd att fungera som agent och som har visat att de försämras i sin sjukdom på den sista terapi. al amyloidosisdarzalex is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (al) amyloidosis.

Eiropas Savienība - zviedru - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - tafasitamab - lymphoma, large b-cell, diffuse - antineoplastiska medel - minjuvi is indicated in combination with lenalidomide followed by minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) who are not eligible for autologous stem cell transplant (asct).

Eiropas Savienība - zviedru - EMA (European Medicines Agency)

janssen-cilag international n.v. - teclistamab - multipelt myelom - antineoplastiska medel - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Eiropas Savienība - zviedru - EMA (European Medicines Agency)

janssen-cilag international n.v. - talquetamab - multipelt myelom - antineoplastiska medel - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.